EMA Authorised: Pylclari (Piflufolastat (18F)) — Curium Pet France

View source ↗

Summary

The EMA authorised Pylclari (Piflufolastat (18F)) for PET imaging to detect prostate cancer lesions; the marketing authorisation holder is Curium Pet France.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pylclari (Piflufolastat (18F))

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Curium Pet France. Decision date: 02/03/2026